Mirum Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.mirumpharma.com

Moat Score
Safety Score

Market Cap $1.95B
PE -22
Debt $308.08M
Cash $222.50M
EV $2.03B
FCF $9.33M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$87.94M
EBIT	-$86.91M
ROE	-39%
ROA	-13%
FCF	$9.33M
Equity	$225.64M
Growth Stability	1
PE	-22.12
PB	8.62
P/FCF	208.48
P/S	5.78
Price/Cash	0.11
Debt/Equity	1.37
Debt/FCF	33.01
Net Margins	-26%
Op. Margins	-26%
Sales Growth YoY	43%
Sales Growth QoQ	10%
Sales CAGR	52%
Equity CAGR	12%
Earnings Growth YoY	-33%

Earnings Growth QoQ	67%
Sales CAGR 5Y	158%
Equity CAGR 5Y	16%
Earnings CAGR 3Y	143%
Sales CAGR 3Y	143%
Equity CAGR 3Y	36%
Market Cap	$1.95B
Revenue	$336.89M
Assets	$670.75M
Total Debt	$308.08M
Cash	$222.50M
Shares Outstanding	47.52M
EV	2.03B
Moat Score	3%
Safety Score	70%
Working Capital	266.24M
Current Ratio	3.1
Shares Growth 3y	19%
Equity Growth QoQ	-3%
Equity Growth YoY	-9%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

SEC Filings

Direct access to Mirum Pharmaceuticals, Inc. (MIRM) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Mirum Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Mirum Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Mirum Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Mirum Pharmaceuticals, Inc..

Years

Calculation mode

= $93M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$9.3M	$93M
DCF		$8.5M	$7.7M	$7M	$6.4M	$5.8M	$5.3M	$4.8M	$4.4M	$4M	$3.6M	$36M
Value	$93M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-439%	-176%	-88%	-26%	-26%
ROA	-36%	-43%	-28%	-37%	-17%	-13%	-13%
ROE	-40%	-60%	-70%	-96%	-66%	-39%	-39%

Bad Net Margins (-26.1%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-0	-4.31	33.01	33.01
Debt over Equity	-	-	-	0	1.23	1.37	1.37
Growth Stability	-	-	-	-	-	-	1

Bad Debt/FCF ratio (33.01)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.37)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	303%	142%	81%	158%
Earnings YoY growth	-	97%	-19%	62%	20%	-46%	-
Equity YoY growth	-	32%	-30%	18%	75%	-9%	16%
FCF YoY growth	-	125%	49%	-9%	-41%	-113%	-